Relation between Cardiac Injury and Elevated Levels of Inflammatory Biomarkers in Patients with Severe COVID-19

Li, Jing.; Sun, Lijie; Wang, Fang; Liu, Bing; LI, Hui; Tang, Guodong; Chang, Zhigang; Liu, Aihua; Fu, Chunyi; Lv, You; Gao, Jing

doi:10.15212/CVIA.2019.1264

Abstract

Background: Since early December 2019, coronavirus disease 2019 (COVID-19) has emerged as a global pandemic and public health crisis. This study aims to explore the relationship between cardiac injury and inflammatory biomarkers in patients with severe COVID-19.

Methods: We collected data on 91 patients with a confirmed diagnosis of severe COVID-19 from February 8 to March 31, 2020. Demographic characteristics, clinical data, and in-hospital outcomes were compared. The relationship between cardiac injury and inflammatory biomarkers was analyzed. Logistic regression was used to explore the independent risk factors for cardiac injury.

Results: The mean age of all patients was 61 years±14 years. About half of the patients were male. Hypertension and coronary heart disease were more common in the cardiac injury group. The levels of inflammatory biomarkers in patients who experienced cardiac injury were generally higher than the levels of those without cardiac injury, including interleukin-6, interleukin-2 receptor (IL-2R), procalcitonin, and high-sensitivity C-reactive protein. There were positive correlations between the levels of high-sensitivity troponin I and N-terminal prohormone of brain natriuretic peptide and the levels of inflammatory biomarkers. Logistic regression shows that IL-2R (odds ratio 1.001, 95% confidence interval 1.000–1.002, P=0.045) and comorbidities (odds ratio 4.909, 95% confidence interval 1.231–19.579, P=0.024) are independent risk factors for cardiac injury in patients with severe COVID-19.

Conclusion: High levels of inflammatory biomarkers are associated with higher risk of cardiac injury in patients with severe COVID-19. IL-2R and comorbidities are predictors of cardiac injury.

Main article text

Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has high invasiveness and has emerged as a global pandemic and public health crisis, and the numbers of infections and deaths are rising [1, 2]. Recent research found that cardiac injury is associated with a high risk of in-hospital death among patients with COVID-19 in Wuhan, China [3–5]. Some research shows that elevated levels of inflammatory biomarkers are linked to the severity of COVID-19 [6–8]. However, there are limited data on the relationship between cardiac injury and inflammatory biomarkers in patients with severe COVID-19. This study aims to examine the potential relationship between cardiac injury and inflammatory biomarkers by retrospectively analyzing data from patients with severe COVID-19 in a hospital in Wuhan.

Methods

Study Participants

The single-center, retrospective, observational study was performed at Tongji Hospital, Wuhan, which was supported by the medical team of Beijing Hospital. We collected data from 100 patients from February 8 to March 31, 2020. COVID-19 was diagnosed in the patients according to “Diagnosis and Treatment of Corona virus Disease-19 (7th trial edition).” [9]. All patients were classified as having severe COVID-19. Diagnosis of severe COVID-19 required at least one of the following criteria to be met: (1) dyspnea, respiratory frequency of 30 or greater minutes; (2) blood oxygen saturation of 93% or less at rest; (3) PaO2/FiO2 ratio of 300 or less. Diagnosis of critical COVID-19 required at least one of the following criteria to be met: (1) respiratory failure with mechanical ventilation; (2) septic shock; (3) transfer to the intensive care unit because of multiple-organ failure [9]. Real-time reverse transcription PCR was used to confirm SARS-CoV-2 infection in all patients. Nine patients were excluded because of the lack of cardiac biomarkers, including the values of high-sensitivity troponin I (hsTnI) and N-terminal prohormone of brain natriuretic peptide (NT-proBNP). All patients were discharged up to March 31, 2020, except for the patients who died.

The 91 patients included in the analysis were divided into a cardiac injury group (n=22) and a non-cardiac-injury group (n=69) according to the serum levels of hsTnI and NT-proBNP. Cardiac injury was defined as plasma hsTnI level greater than 34.2 pg/mL and/or NT-proBNP level greater than 450 pg/mL for patients younger than 50 years, greater than 900 pg/mL for patients aged between 50 and 75 years, and greater than 1800 pg/mL for patients older than 75 years [10].

Data Collection

We collected and analyzed the demographic characteristics (age and sex), clinical data (symptoms, comorbidities, vital signs on admission, laboratory examination results, treatment measures, time, and outcomes) from patients’ medical records. Laboratory examinations were conducted within 24 hours after admission, including a complete blood count, levels of inflammatory biomarkers, coagulation profile, renal and liver function, hsTnI level, and NT-proBNP level. Time included hospitalization and time from onset to admission. The inflammatory biomarkers included interleukin-6 (IL-6), IL-1β, IL-2 receptor (IL-2R), IL-8, IL-10, procalcitonin, ferritin, tumor necrosis factor, and high-sensitivity C-reactive protein (hsCRP). Measurements were repeated according to a change in illness while patients were in the hospital. The longest observed duration in survivors was 48 days.

Statistical Analysis

Continuous variables are expressed as the mean±standard deviation or the median and the interquartile range, and categorical variables are expressed as the number and the percentage. The means of continuous variables were compared by use of the independent group t test or the Mann-Whitney U test, as appropriate. The Pearson correlation coefficient and Spearman rank correlation were used for linear correlation analysis. Proportions for categorical variables were compared by the χ² test or Fisher’s exact test. Logistic regression analysis was used to further determine the predictors of cardiac injury. Statistical analyses were performed and figures were constructed with use of IBM SPSS Statistics (version 25) for all analyses. A two-sided α of less than 0.05 was considered statistically significant.

Result

A total of 91 patients between February 8 and March 31, 2020 were included in the analysis. Twenty-two patients (24.18%) had cardiac injury. The mean age of all patients was 61 years±14 years, ranging from 18 to 91 years. The most frequent initial symptom was fever (62 patients [68.1%]) (Table 1). In all patients, hypertension (37 patients [40.7%]) was the most frequent comorbidity. Patients with cardiac injury stayed longer in the hospital than those without cardiac injury. By April 10, 2020, four patients (4.4%) had died, all in the non-cardiac-injury group.

Table 1

Demographic and Clinical Characteristics of Patients with Coronavirus Disease 2019 (COVID-19).

Characteristic	All patients (n=91)	Patients with cardiac injury (n=22)	Patients without cardiac injury (n=69)	P
Age, years, mean (SD)	61 (14)	65 (17)	59 (13)	0.155
Male	52 (57.1%)	17 (77.3%)	35 (50.7%)	0.052
Initial symptoms
Fever	62 (68.1%)	11 (50%)	51 (73.9%)	0.067
Cough	56 (61.5%)	12 (54.5%)	44 (63.8%)	0.601
Dyspnea	5 (5.5%)	4 (18.2%)	1 (1.4%)	0.014
Headache	4 (4.4%)	1 (4.5%)	3 (4.3%)	1.000
Sore throat	3 (3.3%)	1 (4.5%)	2 (2.9%)	1.000
Muscle ache	4 (4.4%)	1 (4.5%)	3 (4.3%)	1.000
Chest distress	13 (14.3%)	8 (36.4%)	4 (5.8%)	0.665
Chest pain	2 (2.2%)	1 (4.5%)	1 (1.4%)	0.978
Fatigue	11 (12.1%)	5 (22.7%)	6 (8.7%)	0.167
Nausea	2 (2.2%)	2 (9.1%)	0 (0%)	0.09
Comorbidities
Hypertension	37 (40.7%)	15 (68.2%)	22 (31.9%)	0.006
CHD	12 (13.2%)	7 (31.8%)	5 (7.2%)	0.007
Diabetes	20 (22%)	8 (36.4%)	12 (17.4%)	0.078
Cerebrovascular disease	4 (4.4%)	0 (0%)	4 (5.8%)	0.577
Chronic lung disease*	12 (13.2%)	2 (9.1%)	10 (14.5%)	0.723
Endocrine and metabolic diseases^†	5 (5.7%)	3 (15.8%)	2 (2.9%)	0.112
Cancer	12 (13.2%)	4 (18.2%)	8 (11.6%)	0.474
Vital signs on admission
SBP, mmHg, mean (SD)	136 (17)	140 (17)	134 (18)	0.223
DBP, mmHg, mean (SD)	83 (12)	85 (11)	82 (12)	0.421
HR, bpm, median (IQR)	93 (78–102)	88 (75–101)	94 (80–103)	0.151
Spo ₂ ^‡, %, median (IQR)	97 (94–98)	96 (93–97)	97 (95–99)	0.022
Breathing rate, breaths per minute, median (IQR)	20 (19–22)	20 (19–24)	20 (19–21)	0.196
Therapy
Antiviral	83 (91.2%)	20 (90.9%)	63 (91.3%)	1.000
Antibiotic	33 (36.3%)	7 (31.8%)	25 (37.7%)	0.808
Traditional Chinese medicine	55 (60.4%)	14 (63.6%)	41 (59.4%)	0.919
Time
From onset to admission, days, median (IQR)	14 (7–28)	10 (4–20)	14 (10–28)	0.078
Hospitalization, days, mean (SD)	28 (15)	35 (15)	25 (15)	0.013
Death	4 (4.4%)	0 (0%)	4 (5.8%)	0.569

Data are shown as the mean and the standard deviation (SD) in parentheses, the median and the interquartile range (IQR) in parentheses, or the number and the percentage in parentheses.

CHD, coronary heart disease; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure; Spo₂, percutaneous oxygen saturation.

*Including chronic bronchitis, bronchiectasis, emphysema, tuberculosis, and chronic obstructive pulmonary disease.

^†Including hyperthyroidism, hypothyroidism, and hyperlipidemia.

^‡Oxygen saturation was measured on admission after the patient had received oxygen therapy.

Patients in the cardiac injury group had significantly higher levels of hsTnI and NT-proBNP, as expected (Table 2). The white blood cell count, neutrophil count, prothrombin time, thrombin time, D-dimer level, and creatinine level were higher in the patients with cardiac injury than in the patients without cardiac injury (Table 2).

Table 2

Laboratory Findings for Different Groups of Patients.

Characteristic	With cardiac injury (n=22)	Without cardiac injury (n=69)	P
hsTnI, pg/mL	14.60 (3.88–64.68)	2.70 (1.90–6.70)	<0.001
NT-proBNP, pg/mL	773.50 (516.5–1546.5)	76.00 (31.25–189.25)	<0.001
Complete blood cell count
White blood cell count, ×10⁹/L	8.64 (4.58–10.44)	5.79 (4.12–7.40)	0.041
Neutrophil count, ×10⁹/L	7.40 (3.05–8.63)	3.72 (2.33–5.28)	0.005
Lymphocyte count, ×10⁹/L	0.91 (0.74–1.31)	1.23 (0.72–1.66)	0.478
Platelet count, ×10⁹/L	185 (149–287)	231 (174–302)	0.126
Hemoglobin, g/L	121 (102–139)	122 (108–132)	0.771
Coagulation profile
PT, s	14.3 (13.5–15.3)	13.9 (13.4–14.1)	0.049
APTT, s	39.3 (37.8–45.1)	39.0 (35.7–41.7)	0.325
TT, s	16.7 (15.5–18.9)	15.7 (15.2–16.7)	0.035
Fibrinogen, g/L	4.85 (3.82–5.97)	4.9 3 (4.03–5.89)	0.725
D-dimer, mg/L	2.31 (1.03–9.40)	0.99 (0.40–2.66)	0.011
Renal and liver function
ALT, U/L	28 (12–43)	19 (12–40)	0.291
Creatinine, μmol/L	77 (62–104)	63 (54–82)	0.047
eGFR, mL/(min 1.73 m²)	86.2 (57.4–100.8)	96.1 (82.5–104.2)	0.054

Data are shown as the median and the interquartile range in parentheses.

ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; eGFR, estimated glomerular filtration rate; hsTnI, high-sensitivity troponin I; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PT, prothrombin time; TT, thrombin time.

Table 3 shows that the peak values of inflammatory biomarkers in the cardiac injury group were generally higher than those in the group without cardiac injury. Although the IL-8 level was higher in patients without cardiac injury, the levels in both groups were within the normal range (<62 pg/mL). Figures 1 and 2 shows that there are positive correlations between the levels of hsTnI and NT-proBNP and the levels of inflammatory biomarkers.

Table 3

Peak Levels of Inflammatory Biomarkers for Different Groups of Patients in the Hospital.

Inflammatory biomarker	With cardiac injury (n=22)	Without cardiac injury (n=69)	P
hsCRP, pg/mL	68.70 (11.33–110.60)	11.50 (2.75–48.85)	0.013
Procalcitonin, pg/mL	0.14 (0.07–0.44)	0.07 (0.03–0.12)	0.008
TNF, pg/mL	10.80 (8.65–16.45)	9.40 (7.65–12.65)	0.110
Ferritin, ng/mL	889.15 (387.78–1581.95)	515.40 (303.60–1551.70)	0.220
Interleukin-1β, pg/mL	5.00 (5.00–5.80)	5.00 (5.00–5.28)	0.303
Interleukin-2 receptor, U/mL	954.00 (723.50–1451.5)	518.00 (339.50–815.00)	<0.001
Interleukin-6, pg/mL	38.09 (16.09–65.88)	7.18 (2.93–25.40)	0.001
Interleukin-8, pg/mL	26.30 (16.30–66.40)	16.50 (8.05–34.95)	0.03
Interleukin-10, pg/mL	5.00 (5.00–12.15)	5.00 (5.00–6.85)	0.235

Data are shown as the median and the interquartile range in parentheses. The normal values are as follows: high-sensitivity C-reactive protein (hsCRP), less than 30 pg/mL; procalcitonin, 0.02–0.05 pg/mL; tumor necrosis factor (TNF), less than 8.1 pg/mL; ferritin, 15–150 ng/mL; interleukin-1β, less than 5.0 pg/mL; interleukin-2 receptor, 223–710 U/mL; interleukin-6, less than 7.0 pg/mL; interleukin-8, less than 62 pg/mL; interleukin-10, less than 9.1 pg/mL.

Figure 1

Correlation between the Levels of High-Sensitivity Troponin I (hsTnI) and Inflammatory Biomarkers.

(A) There are positive correlations between the levels of hsTnI and interleukin-2 receptor (IL-2R) (P=0.001, r=0.352); (B) There are positive correlations between the levels of hsTnI and high-sensitivity C-reactive protein (hsCRP) (P=0.032, r=0.249); (C) There are positive correlations between the levels of hsTnI and interleukin-6 (IL-6) (P=0.02, r=0.556).

Figure 2

Correlation between the Levels of N-terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) and Inflammatory Biomarkers.

(A) There are positive correlations between the levels of NT-proBNP and interleukin-2 receptor (IL-2R) (P<0.001, r=0.612); (B) There are positive correlations between the levels of NT-proBNP and interleukin-6 (IL-6) (P<0.001, r=0.556); (C) There are positive correlations between the levels of NT-proBNP and procalcitonin (PCT) (P<0.001, r=0.476); (D) There are positive correlations between the levels of NT-proBNP and high-sensitivity C-reactive protein (hsCRP) (P<0.001, r=0.494).

Logistic regression analysis was used to assess the effect of age, male sex, comorbidities, IL-2R, and creatinine on cardiac injury in patients with severe COVID-19. Comorbidities included hypertension, coronary heart disease, and diabetes. In univariable logistic regression analysis, male sex, comorbidities, IL-2R and creatinine were risk factors for cardiac injury (Table 4). Multivariable regression analysis showed IL-2R (odds ratio 1.001, 95% confidence interval 1.000–1.002, P=0.023) and comorbidities (odds ratio 4.909, 95% confidence 1.231–19.579, P=0.024) are independent risk factors for cardiac injury in patients with severe COVID-19 (Table 4).

Table 4

Univariate and Multivariate Logistic Regression Analysis of Risk Factors for Cardiac Injury.

Variable	Univariate analysis			Multivariate analysis
Variable	OR	95% CI	P	OR	95% CI	P
Male sex	0.303	0.100–0.912	0.034	0.320	0.081–1.265	0.104
Age	1.025	0.990–1.061	0.160	0.987	0.940–1.036	0.596
IL-2R	1.001	1.000–1.002	0.007	1.001	1.000–1.002	0.023
Creatinine	1.018	1.002–1.034	0.025	1.007	0.989–1.025	0.475
Comorbidities*	4.148	1.44–11.92	0.008	4.909	1.231–19.579	0.024

CHD, coronary heart disease; CI, confidential interval; IL-2R, interleukin-2 receptor, OR, odds ratio.

*Including hypertension, coronary heart disease, and diabetes.

Discussion

This retrospective cohort study elicited three main findings. First, the occurrence of cardiac injury is not uncommon, and the incidence reaches 24.18% in patients with severe COVID-19. Second, elevated levels of inflammatory biomarkers and cardiovascular disease are more prevalent in the cardiac injury group. Finally, IL-2R and preexisting cardiovascular disease are independent risk factors for cardiac injury in patients with severe COVID-19.

Several retrospective studies exploring the relationship between cardiac injury and mortality in COVID-19 patients have been published. Shi et al. [3] and Guo et al. [11] both reported COVID-19 patients with cardiac injury have higher levels of C-reactive protein and procalcitonin. Consistently, our study also found that patients with severe COVID-19 with cardiac injury have evidence of severer systemic inflammation, including higher levels of IL-6, IL-2R, hsCRP, and procalcitonin. Our study participants were mainly patients with severe COVID-19. Moreover, our research provides information not reported by previous research, and first demonstrates that IL-2R and underlying cardiovascular disease are independently associated with increased risk of cardiac injury in patients with severe COVID-19.

Huang et al. [6] found that COVID-19 patients admitted to the intensive care unit (ICU) had higher plasma levels of cytokines, including IL-2, IL-7, IL-10, and tumor necrosis factor than those non-ICU patients. This indicates that critical COVID-19 patients may experience the cytokine storm, an uncontrolled and dysfunctional immune response [12, 13]. In the present study, the levels of inflammatory biomarkers had positive correlations with the levels of hsCRP and NT-proBNP in patients with severe COVID-19, suggesting that a cytokine storm may contribute to myocardial injury and left ventricular impairment. Patients with cardiac injury had higher levels of inflammatory biomarkers, including white blood cell count, neutrophil count, hsCRP level, and procalcitonin level. So we speculate that inflammation plays an important role in cardiac injury. Inflammation may cause endothelial cell dysfunction and increase the procoagulant activity of blood, which can lead to the rupture of coronary plaque [14–17].

Among all the cytokines studied, the effect of IL-2R on cardiac injury is particularly prominent. IL-2, a T-cell growth factor, and IL-2R have been found in plaque [18, 19]. Previous research found that IL-2R regulates lymphocyte activation, plays an important role in atherosclerosis, and positively relates to the occurrence of cardiovascular disease [20–22]. IL-2 promotes regulatory T cells and may have an atheroprotective role [23]. So we presume that because of SARS-CoV-2 invasion and lymphopenia [24], the interaction of excessively secreted IL-2 and IL-2R promotes the development of atherosclerosis and advanced cardiac injury.

By April 10, 2020, 95.6% of patients in our study had been discharged from hospital, and mortality was 4%. Although we did not find statistical differences in mortality regarding patients with severe COVID-19 with or without cardiac injury on admission, patients with cardiac injury stayed longer in the hospital than patients without cardiac injury. Long-term observation is needed to confirm the impact of elevated levels of inflammation biomarkers on the prognosis of patients with severe COVID-19 with cardiac injury.

Limitations

Our research has several limitations. Firstly, it was a small sample, single-center, and retrospective study, and selection bias may not be avoided in this study. At the same time, a small sample size might lead to overfitting. Secondly, some results of cardiac examinations, such as electrocardiogram and cardiac ultrasonography, are incomplete in our study, resulting in our being unable to comprehensively describe the cardiac function. Thirdly, because of quick outbreaks and urgent treatment needs, changes in the levels of inflammatory biomarkers were not detected regularly. Data from larger populations and multiple centers are warranted to confirm the dynamic change of the levels of inflammatory biomarkers.

Conclusion

In conclusion, inflammatory biomarkers play an important role in cardiac injury in patients with severe COVID-19. Further studies with a large sample size are needed to verify our findings.

Funding

The study was funded by the Beijing Municipal Natural Science Foundation (no. 7192078).

Ethics approval

This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Commission of Beijing Hospital (2020BJYYEC-035-01). The requirement for written informed consent was waived because of the context of an emerging infectious disease.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

K Sun, J Chen, C Viboud. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet Digit Health 2020;2:e201–8.
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536–44.
S Shi, M Qin, B Shen, Y Cai, T Liu, F Yang, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802–10.
RO Bonow, GC Fonarow, PT O’Gara, CW Yancy. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol 2020;5:751–3.
H Han, L Xie, R Liu, J Yang, F Liu, K Wu, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol 2020;92:819–23.
C Huang, Y Wang, X Li, L Ren, J Zhao, Y Hu, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.
F Liu, L Li, M Xu, J Wu, D Luo, Y Zhu, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127: 104370.
X Xu, MQ Yu, Q Shen, LZ Wang, RD Yan, MY Zhang, et al. Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China. Int J Med Sci 2020;17(13):2052–62.
General Office of National Health Commission of the People’s Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of corona virus disease-19 (7th trial edition). Chin Med 2020;15:801–5.
Chinese heart failure diagnosis and treatment guidelines 2018. Chin J Heart Fail Cardiomyopathy 2018;2:196–225.
T Guo, Y Fan, M Chen, X Wu, L Zhang, T He, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:811–8.
M Eccleston-Turner, A Phelan, R Katz. Preparing for the next pandemic – the WHO’s global influenza strategy. N Engl J Med 2019;381:2192–4.
JR Teijaro, KB Walsh, S Rice, H Rosen, MB Oldstone. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A 2014;111:3799–804.
G Tersalvi, M Vicenzi, D Calabretta, L Biasco, G Pedrazzini, D Winterton. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. J Card Fail 2020;26:470–5.
N Tang, D Li, X Wang, Z Sun. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.
M Madjid, D Vela, H Khalili-Tabrizi, SW Casscells, S Litovsky. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes. Tex Heart Inst J 2007;34(1):11–8.
VF Corrales-Medina, M Madjid, DM Musher. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010;10(2):83–92.
DA Morgan, FW Ruscetti, R Gallo. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193: 1007–8.
S Gillis, KA Smith. Long term culture of tumour-specific cytotoxic T cells. Nature 1977;268:154–6.
P Durda, J Sabourin, EM Lange, MA Nalls, JC Mychaleckyj, NS Jenny, et al. Plasma levels of soluble interleukin-2 receptorα: associations with clinical cardiovascular events and genome-wide association scan. Arterioscler Thromb Vasc Biol 2015;35:2246–53.
Z Zeng, K Yu, L Chen, W Li, H Xiao, Z Huang. Interleukin-2/anti-Interleukin-2 immune complex attenuates cardiac remodeling after myocardial infarction through expansion of regulatory T cells. J Immunol Res 2016;2016:8493767.
H Bakhshi, V Varadarajan, B Ambale-Venkatesh, Z Meyghani, MR Ostovaneh, P Durda, et al. Association of soluble interleukin-2 receptorαand tumour necrosis factor receptor 1 with heart failure: The Multi-Ethnic Study of Atherosclerosis. ESC Heart Fail 2020;7:639–44.
T Dietrich, T Hucko, C Schneemann, M Neumann, A Menrad, J Willuda, et al. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells. Atherosclerosis. 2012;220:329–36.
Z Wu, JM McGoogan. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239–42.

Author and article information

Journal

Journal ID (publisher-id): CVIA

Title: Cardiovascular Innovations and Applications

Abbreviated Title: CVIA

Publisher: Compuscript (Ireland )

ISSN (Electronic): 2009-8782

ISSN (Print): 2009-8618

Publication date (Print): February 2021

Publication date (Electronic): February 2021

Volume: 5

Issue: 3

Pages: 165-172

Affiliations

[1] ¹Division of Cardiology, Beijing Hospital, 100730 Beijing, China

[2] ²Division of Cardiology, Xuanwu Hospital Capital Medical University, 100053 Beijing, China

[3] ³Division of Intensive Care Unit, Beijing Hospital, 100730 Beijing, China

[4] ⁴Division of Rheumatology and Immunology, Beijing Hospital, 100730 Beijing, China

[5] ⁵Division of Emergency, Beijing Hospital, 100730 Beijing, China

[6] ⁶National Clinical Research Center of Geriatric Disease, Xuanwu Hospital, 100053 Beijing, China

Author notes

Correspondence: Jing Li, MD, PhD, Division of Cardiology, Beijing Hospital, Beijing, China, E-mail: leejingabc@ 123456sina.com ; Jing Gao, MD, PhD, Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China, E-mail: gaojing_gao@ 123456sina.com ; and Jing Li, MD, PhD, FESC, Division of Cardiology, Xuanwu Hospital Capital Medical University, Beijing, China, E-mail: shpxbb@ 123456sina.com

^aContributed equally to the manuscript.

Article

Publisher ID: cvia.2019.1264

DOI: 10.15212/CVIA.2019.1264

SO-VID: 20125234-d74b-4272-931f-3b08baf3d717

License:

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 Unported License (CC BY-NC 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See https://creativecommons.org/licenses/by-nc/4.0/.

History

Date received : 22 September 2020

Date revision received : 30 October 2020

Date accepted : 7 November 2020

Comments

[1] K Sun, J Chen, C Viboud. Early epidemiological analysis of the coronavirus disease 2019 outbreak based on crowdsourced data: a population-level observational study. Lancet Digit Health 2020;2:e201–8.

[2] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536–44.

[3] S Shi, M Qin, B Shen, Y Cai, T Liu, F Yang, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802–10.

[4] RO Bonow, GC Fonarow, PT O’Gara, CW Yancy. Association of coronavirus disease 2019 (COVID-19) with myocardial injury and mortality. JAMA Cardiol 2020;5:751–3.

[5] H Han, L Xie, R Liu, J Yang, F Liu, K Wu, et al. Analysis of heart injury laboratory parameters in 273 COVID-19 patients in one hospital in Wuhan, China. J Med Virol 2020;92:819–23.

[6] C Huang, Y Wang, X Li, L Ren, J Zhao, Y Hu, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497–506.

[7] F Liu, L Li, M Xu, J Wu, D Luo, Y Zhu, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127: 104370.

[8] X Xu, MQ Yu, Q Shen, LZ Wang, RD Yan, MY Zhang, et al. Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China. Int J Med Sci 2020;17(13):2052–62.

[9] General Office of National Health Commission of the People’s Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of corona virus disease-19 (7th trial edition). Chin Med 2020;15:801–5.

[10] Chinese heart failure diagnosis and treatment guidelines 2018. Chin J Heart Fail Cardiomyopathy 2018;2:196–225.

[11] T Guo, Y Fan, M Chen, X Wu, L Zhang, T He, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020;5:811–8.

[12] M Eccleston-Turner, A Phelan, R Katz. Preparing for the next pandemic – the WHO’s global influenza strategy. N Engl J Med 2019;381:2192–4.

[13] JR Teijaro, KB Walsh, S Rice, H Rosen, MB Oldstone. Mapping the innate signaling cascade essential for cytokine storm during influenza virus infection. Proc Natl Acad Sci U S A 2014;111:3799–804.

[14] G Tersalvi, M Vicenzi, D Calabretta, L Biasco, G Pedrazzini, D Winterton. Elevated troponin in patients with coronavirus disease 2019: possible mechanisms. J Card Fail 2020;26:470–5.

[15] N Tang, D Li, X Wang, Z Sun. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020;18:844–7.

[16] M Madjid, D Vela, H Khalili-Tabrizi, SW Casscells, S Litovsky. Systemic infections cause exaggerated local inflammation in atherosclerotic coronary arteries: clues to the triggering effect of acute infections on acute coronary syndromes. Tex Heart Inst J 2007;34(1):11–8.

[17] VF Corrales-Medina, M Madjid, DM Musher. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis 2010;10(2):83–92.

[18] DA Morgan, FW Ruscetti, R Gallo. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 1976;193: 1007–8.

[19] S Gillis, KA Smith. Long term culture of tumour-specific cytotoxic T cells. Nature 1977;268:154–6.

[20] P Durda, J Sabourin, EM Lange, MA Nalls, JC Mychaleckyj, NS Jenny, et al. Plasma levels of soluble interleukin-2 receptorα: associations with clinical cardiovascular events and genome-wide association scan. Arterioscler Thromb Vasc Biol 2015;35:2246–53.

[21] Z Zeng, K Yu, L Chen, W Li, H Xiao, Z Huang. Interleukin-2/anti-Interleukin-2 immune complex attenuates cardiac remodeling after myocardial infarction through expansion of regulatory T cells. J Immunol Res 2016;2016:8493767.

[22] H Bakhshi, V Varadarajan, B Ambale-Venkatesh, Z Meyghani, MR Ostovaneh, P Durda, et al. Association of soluble interleukin-2 receptorαand tumour necrosis factor receptor 1 with heart failure: The Multi-Ethnic Study of Atherosclerosis. ESC Heart Fail 2020;7:639–44.

[23] T Dietrich, T Hucko, C Schneemann, M Neumann, A Menrad, J Willuda, et al. Local delivery of IL-2 reduces atherosclerosis via expansion of regulatory T cells. Atherosclerosis. 2012;220:329–36.

[24] Z Wu, JM McGoogan. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA 2020;323:1239–42.

Cardiovascular Innovations and Applications